A5011731170- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Computational Drug Discovery Methods
- Advanced Biosensing Techniques and Applications
- Monoclonal and Polyclonal Antibodies Research
- Molecular Biology Techniques and Applications
- Cancer Immunotherapy and Biomarkers
- Ferroptosis and cancer prognosis
- Radiomics and Machine Learning in Medical Imaging
- RNA modifications and cancer
- Gene expression and cancer classification
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Cancer-related molecular mechanisms research
- Long-Term Effects of COVID-19
- Advanced Fluorescence Microscopy Techniques
- Cell Image Analysis Techniques
- Renal and related cancers
- Distributed Control Multi-Agent Systems
- Immune cells in cancer
- Mathematical and Theoretical Epidemiology and Ecology Models
- S100 Proteins and Annexins
- Epigenetics and DNA Methylation
- MicroRNA in disease regulation
- Neural Networks Stability and Synchronization
Fudan University Shanghai Cancer Center
2021-2024
Shanghai Cancer Institute
2024
Shanghai Medical College of Fudan University
2021-2024
Fudan University
2020-2022
Shanghai Municipal People's Government
2016
The molecular heterogeneity and distinct features of HER2-low breast cancers, particularly in the Chinese population, are not well understood, limiting its precise management era antibody‒drug conjugates. To address this issue, we established a cohort 434 patients with cancer (433 female one male) integrated genomic, transcriptomic, proteomic, metabolomic profiling data. In cohort, tumors more distinguished from HER2-0 hormone receptor-negative subgroup. Within tumors, significant...
HER2-positive breast cancer is an aggressive subtype that accounts for 15% to 20% of all cancers. Recent studies have suggested a group heterogeneous diseases with different sensitivities standard treatment regimens. Revealing the molecular heterogeneity could potentially enable more precise strategies. In this study, we performed multiomics profiling on cohort and identified four transcriptome-based subtypes. The classical HER2 (HER2-CLA) comprised 28.3% samples displayed high ERBB2...
The pandemic of the coronavirus disease 2019 (COVID‐19) has posed huge threats to healthcare systems and global economy. However, host response towards COVID‐19 on molecular cellular levels still lacks full understanding effective therapies are in urgent need. Here, we integrate three datasets, GSE152641, GSE161777, GSE157103. Compared healthy people, 314 differentially expressed genes were identified, which mostly involved neutrophil degranulation cell division. protein‐protein network was...
<div>Abstract<p>HER2-positive breast cancer is an aggressive subtype that accounts for 15% to 20% of all cancers. Recent studies have suggested HER2-positive a group heterogeneous diseases with different sensitivities standard treatment regimens. Revealing the molecular heterogeneity could potentially enable more precise strategies. In this study, we performed multiomics profiling on cohort and identified four transcriptome-based subtypes. The classical HER2 (HER2-CLA) comprised...
Abstract The associated article reports multiomic analysis of breast cancers, where we provided a unique public resource that contributes novel insights into the cancer, holding promise for further precision treatment approaches. This protocol not only delineates detailed experimental procedures sample preparation and data generation but also comprehensive methods genomics, transcriptomics, proteomics, metabolomics from cancer samples. Furthermore, regarding radiomics pathomics, describes...
This paper investigates the leader-follower problem in presence of potential actuator faults. We focus on continuous-time multi-agent uncertain systems with a directed network topology. Time-varying fault parameters are considered, which relax assumption prior work that all followers must be fixed. assume these can sampled an intermittent manner. Based samples, cooperative control law is updated according to proposed tolerant strategy. It shown if sampling condition, terms LMIs, satisfied,...
<p>Figure S4</p>
<p>Table S1</p>
<p>Table S5</p>
<p>Figure S7</p>
<p>Table S4</p>
<p>Table S3</p>
<p>Figure S3</p>
<p>Table S2</p>
<p>Figure S1</p>
<p>Figure S2</p>
<p>Supplemental Materials and Methods</p>
<p>Figure S5</p>
<p>Figure S6</p>
Abstract The associated article reports multiomic analysis of breast cancers, where we provided a unique public resource that contributes novel insights into the cancer, holding promise for further precision treatment approaches. This protocol not only delineates detailed experimental procedures sample preparation and data generation but also comprehensive methods genomics, transcriptomics, proteomics, metabolomics from cancer samples. Furthermore, regarding radiomics pathomics, describes...
Abstract Background: Anti-HER2 targeted therapy has achieved a series of breakthroughs. However, the current treatment strategy regarding HER2-positive breast cancer remains indiscriminate and lacks specificity, which limits further improvement overall response may lead to overtreatment extra cost for some patients. Our study aims reveal molecular heterogeneity guide more precise treatment. Patients methods: We selected patients treated at Fudan University Shanghai Cancer Center between 2013...